Amgen Continues To Feel COVID-19 Sales Impact In Q1
Otezla Stands Out For Coming In $100m Below Consensus
Patients’ COVID-19 anxiety continues to keep them from seeking treatments for psoriasis, migraine and even cancer, Amgen said, blaming the pandemic for much of its 4% decline in first quarter revenue.
You may also be interested in...
With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.
Together with a similar delay for AbbVie’s Rinvoq, the delays appear to stem from a study that raised concerns about the class. But the potential sales impact is less clear.
A new pilot program by the insurer is offering a $500 debit card to patients who switch from the blockbuster Novartis psoriasis drug to Lilly's rival Taltz or other preferred drugs.